DexCom, Inc. (NASDAQ: DXCM) shares exhibited a bullish surge in the preceding trading session, marking a notable uptick of 9.80% to settle at $133.72. This rise in DexCom’s stock value was precipitated by a significant regulatory endorsement received for one of its flagship products.
The Federal Drug Authority (FDA) recently granted clearance to Stelo by DexCom (DXCM) – heralded as the pioneering glucose biosensor that circumvents the necessity for a medical prescription. Within the United States, an estimated 25 million individuals diagnosed with Type 2 diabetes, not reliant on insulin, stand to derive benefits from continuous glucose monitoring (CGM) technology.
While Dexcom G7 is accessible with a prescription, the clearance of Stelo for non-prescription use serves to further streamline access to cutting-edge CGM technology, particularly for those without insurance coverage for CGM. Dexcom remains at the forefront of innovation within the CGM sector, boasting a distinguished record of pioneering advancements.
Notably, Dexcom was the initial provider to integrate CGM with multiple insulin delivery systems, connect CGM with smartphones, eliminate the need for fingersticks in treatment decisions, and now, carve out a novel category by introducing the premier glucose biosensor sanctioned for over-the-counter usage. Drawing from its extensive experience catering to individuals with Type 2 diabetes not reliant on insulin, DXCM has tailored Stelo to meet their distinct requirements.
Continuous glucose monitoring stands as a cornerstone in the management of Type 2 diabetes, with demonstrable benefits whether utilized independently or in conjunction with other diabetes and weight management medications. Research underscores that the adoption of Dexcom continuous glucose monitoring among individuals with Type 2 diabetes correlates with substantial enhancements in time within target glucose range, A1c levels, and overall quality of life.
Embracing CGM technology can empower individuals with diabetes to comprehend the effects of dietary choices and physical activity on their glucose levels. However, for those newly diagnosed with Type 2 diabetes or not undergoing insulin therapy, such devices often fall beyond the purview of insurance coverage.
Stelo represents a pivotal avenue for furnishing invaluable insights that can significantly influence diabetes management strategies. Dexcom intends to make Stelo available for online purchase without a prescription by the upcoming summer season.
